CIK 0001609809
- Non-accelerated filer
- Smaller reporting company
Seres Therapeutics, Inc.
Sign in to watch- Ticker
- MCRB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 274326290
- Phone
- +1 617-945-9626
- Business address
- 200 SIDNEY STREET, CAMBRIDGE, MA, 02139
- Former names
- Seres Therapeutics, Inc., Seres Health, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $795
- in 4 filings, $795 under 10b5-1 plans
Net −$795. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 39 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-06-26 | Pomerantz Roger President and CEO | Sale | −21,224 | $9.19 | $195K | 228,304 |
| 2018-06-26 | Pomerantz Roger President and CEO | Exercise or conversion · STOCK OPTION (RIGHT TO BUY) | −21,224 | 873,929 | ||
| 2018-06-26 | Kim Lorence H. Director | Grant or award · Stock Option (right to buy) | +15,000 | 15,000 | ||
| 2018-06-26 | AFEYAN NOUBAR Director | Grant or award · Stock Option (right to buy) | +15,000 | 15,000 | ||
| 2018-06-26 | Behar Gregory Director | Grant or award · Stock Option (right to buy) | +15,000 | 15,000 | ||
| 2018-06-26 | Ausiello Dennis A Director | Grant or award · Stock Option (right to buy) | +15,000 | 15,000 | ||
| 2018-06-26 | Graves Kurt Director | Grant or award · Stock Option (right to buy) | +15,000 | 15,000 | ||
| 2018-06-25 | Pomerantz Roger President and CEO | Exercise or conversion | +16,288 | $0.71 | $12K | 255,056 |
| 2018-06-25 | Pomerantz Roger President and CEO | Sale | −26,752 | $9.21 | $247K | 228,304 |
| 2018-06-25 | Pomerantz Roger President and CEO | Exercise or conversion · STOCK OPTION (RIGHT TO BUY) | −16,288 | 895,153 | ||
| 2018-06-22 | Pomerantz Roger President and CEO | Sale | −40,057 | $9.36 | $375K | 238,768 |
| 2018-06-21 | Pomerantz Roger President and CEO | Sale | −18,987 | $9.06 | $172K | 278,825 |
| 2018-06-20 | Pomerantz Roger President and CEO | Sale | −26,492 | $9.33 | $247K | 297,812 |
| 2018-06-19 | Aunins John G. Chief Technology Officer & EVP | Exercise or conversion | +5,000 | 175,206 | ||
| 2018-06-19 | Aunins John G. Chief Technology Officer & EVP | Exercise or conversion · RESTRICTED STOCK UNITS | −5,000 | 10,000 | ||
| 2018-06-15 | Aunins John G. Chief Technology Officer & EVP | Sale | −14,279 | $8.57 | $122K | 170,206 |
| 2018-05-15 | Aunins John G. | Sale | −14,279 | $8.08 | $115K | 146,648 |
| 2018-05-09 | Pomerantz Roger President and CEO | Sale | −233 | $9.00 | $2K | 324,304 |
| 2018-04-25 | Aunins John G. Chief Technology Officer & EVP | Sale | −14,279 | $7.58 | $108K | 184,485 |
| 2018-01-30 | Pomerantz Roger President and CEO | Grant or award · Stock Option (right to buy) | −278,000 | 278,000 |
Page 28 of 34 · 662 trades